DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089
This study is recruiting at 15 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- DualityBio Inc.
- Last updated on ClinicalTrials.gov
- May 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- USA06-0 · Los Angeles, CA
- USA16-0 · Los Angeles, CA
Colorado · 1
- USA01-0 · Wheat Ridge, CO
Florida · 1
- USA08-0 · Florida City, FL
Georgia · 1
- USA10-0 · Atlanta, GA
Maryland · 1
- USA11-0 · Bethesda, MD
Nebraska · 1
- USA14-0 · Lincoln, NE
New York · 1
- USA04-0 · New York, NY
Oregon · 1
- USA15-0 · Portland, OR
South Carolina · 1
- USA03-0 · Charleston, SC
Texas · 2
- USA13-0 · Anderson, TX
- USA12-0 · Houston, TX
Virginia · 1
- USA05-0 · Virginia Beach, VA
Washington · 2
- USA09-0 · Puyallup, WA
- USA07-0 · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.